 Shares of LivaNova NASDAQ:LIVN were unchanged after the company reported Q2 results.Quarterly Results Earnings per share were down 121.43 year over year to 0.15, which beat the estimate of 0.30.Revenue of 182,200,000 declined by 34.27 from the same period last year, which beat the estimate of 169,730,000.Looking Ahead The upcoming fiscal years EPS expected to be between 1.15 and 1.35.The upcoming fiscal years revenue expected to be between 900,000,000 and 1,008,000,000.Conference Call Details Date: Jul 29, 2020View more earnings on LIVNTime: 07:00 AMET Webcast URL: Stock Performance 52-week high: 87.4552-week low: 33.40Price action over last quarter: Up 4.69Company Profile U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions with surgical heart valves, heart-lung machines, and oxygenation equipment as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21 from Europe, and the remainder from the rest of the world.See more from Benzinga Earnings Scheduled For July 29, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 